VentriPoint Diagnostics
Ventripoint Diagnostics is a Canadian public medtech company that sells the AI-powered VMS+ platform, converting standard 2D echocardiograms into MRI-quality 3D heart models for congenital heart disease, pediatric cardiology, and pulmonary hypertension programs at hospitals and remote community health sites globally.
- Company typePublic
- Founded2001
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What VentriPoint Diagnostics does
Ventripoint Diagnostics Ltd. is a publicly traded Canadian medical technology company (TSXV:VPT, OTCQB:VPTDF) headquartered in Toronto that develops the VMS+ platform, an AI-powered cardiac imaging system designed to convert standard 2D echocardiograms into MRI-quality 3D volumetric models of all four heart chambers. Its core technology, the patented Knowledge-Based Reconstruction (KBR) algorithm, combines anatomical landmark detection on 2D echo images with an MRI-validated reference library of normal and pathological adult and pediatric heart morphologies. The latest generation, VMS+ 4.0, adds AI-assisted landmark placement that reduces analysis time by approximately 30% and includes a Global Longitudinal Strain module; the platform integrates with PACS/DICOM and standard ultrasound machines via a proprietary sensor tracking system. Ventripoint holds regulatory clearances in Canada (Health Canada, August 2024), Europe (CE Mark under EU MDR, October 2024), and the United States (FDA 510(k), February 2025), and is pursuing China NMPA approval through partner Lishman Global.
The company serves primarily congenital heart disease (CHD) and pediatric cardiology programs, with secondary applications in pulmonary hypertension, cardiotoxicity surveillance, heart failure, valve disease, and remote/Indigenous community care via hub-and-spoke models. Named customers include Duke University Health Center, German Heart Center Berlin, University of Freiburg Medical Center, Guy's and St Thomas' NHS Foundation Trust, East Midlands Congenital Heart Centre, Evelina London Children's Hospital, and Hospital Metropolitano in Costa Rica. The business model is transitioning from one-time capital equipment sales toward a Device-as-a-Service subscription targeting an 80/20 recurring mix, distributed through regional channel partners (Cardiologic UK, AngioPRO Germany, Lishman Global China), platform integrators (ASCEND Cardiovascular Gen3Echo, LG Consulting Solutions), and emerging markets partners (Montecristo Group, First Light Health). With a current installed base of approximately 25 systems targeted to double to 50, headcount of 11-50 employees, and revenue expected to begin accruing in Q2 2026, Ventripoint is in the early commercial scaling phase following two decades of product development.
VentriPoint Diagnostics firmographics
Firmographics- Name
- VentriPoint Diagnostics
- Legal name
- Ventripoint Diagnostics Ltd.
- Website
- https://ventripoint.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ventripoint Diagnostics is a Canadian public medtech company that sells the AI-powered VMS+ platform, converting standard 2D echocardiograms into MRI-quality 3D heart models for congenital heart disease, pediatric cardiology, and pulmonary hypertension programs at hospitals and remote community health sites globally.
- Ownership category
- akta.pro rank
VentriPoint Diagnostics industry classification
Industry- Product category
- Cardiac Diagnostic Imaging Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industries
- Imaging Workflow Orchestration & Modality Worklist (MWL)/Scheduling (HLACALAE), Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where VentriPoint Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
VentriPoint Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Device-as-a-Service Subscription: Transitioning from capital equipment sales to subscription model (Device-as-a-Service). Monthly or annual subscription for VMS+ software access with ongoing support and updates. Target is 80/20 weighting toward subscription over direct capital purchases.
- Capital Equipment Sales: Traditional one-time capital purchase of VMS+ systems. Currently transitioning to subscription model but maintains flexibility for sites preferring capital purchases.
- Future Cost-per-Use Model: Long-term plan to shift to cost-per-use model as procedure volumes increase, allowing scaling based on actual usage.
- Hardware/Component Sales: Sale of VMS+ hardware systems including sensors and installation components. Company ordered components for 25 systems to support near-term deployment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Device-as-a-Service Subscription Model |
| One time/ perpetual license | Multi-year contract | Capital Equipment Purchase |
Go-to-market motion4 records
Distribution channels9 records
Marketing channels8 records
VentriPoint Diagnostics product offering
Product offeringCore offering
VentriPoint Diagnostics develops and sells the VMS+ cardiac imaging platform, an AI-powered system that transforms standard 2D echocardiograms into MRI-quality 3D models of the heart. The proprietary Knowledge-Based Reconstruction (KBR) algorithm provides volumetric measurements and ejection fractions for all four heart chambers with cMRI-equivalent accuracy. The platform includes the VMS+ hardware/software system with sensor tracking, a workstation-based 3D Echo and MRI software, and add-on modules such as Global Longitudinal Strain analysis, targeting hospitals, cardiac centers, and remote healthcare providers.
Product overview
VentriPoint Diagnostics offers the VMS+ cardiac imaging platform, a unified system comprising software that transforms standard 2D echocardiograms into MRI-quality 3D heart models using proprietary Knowledge-Based Reconstruction (KBR) algorithms. The core VMS+ platform provides volumetric measurements and ejection fractions for all four heart chambers, with particular strength in assessing the difficult-to-image right ventricle. The portfolio includes: (1) VMS+ hardware/software platform that connects to standard ultrasound machines with sensor tracking, (2) VMS+ 3D Echo and MRI Software for workstation installation, and (3) VMS+ Global Longitudinal Strain add-on module. The system is designed for point-of-care use, remote installation capability, and provides results in a three-step workflow within minutes.
Differentiator
Problem solved
Functional benefit
Brands
- VMS+™: AI-powered cardiac imaging platform that transforms standard 2D echocardiograms into MRI-quality 3D heart models using Knowledge-Based Reconstruction (KBR) technology. Provides volumetric measurements and ejection fractions for all four chambers of the heart.
- VMS+ 4.0
Products and services
- VMS+ (Vision Medical System Plus) AI-powered cardiac imaging platform that transforms standard 2D echocardiograms into accurate 3D models of the heart, providing volumetric measurements and ejection fractions for all four chambers with MRI-equivalent accuracy. Designed for point-of-care use with hardware sensor tracking system.
- VMS+ 3D Echo and MRI Software Software application that can be installed on any personal workstation to create 3D models of the heart from commercially available 3D echo or MRI images, providing reproducible and accurate volumetric measurements and ejection fractions.
- VMS+ Global Longitudinal Strain Advanced analysis module that provides 3D-based global longitudinal strain measurements by combining motion data from the whole 3D model into a single measure, without requiring additional images or software licenses.
Quantifiable outcome
- 98% task completion rate with no critical errors in usability study
- +6 more outcomes
Companies that use VentriPoint Diagnostics
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles3 records
VentriPoint Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability6 records
Feature6 records
VentriPoint Diagnostics partnerships and signals
Strategic signalScale indicators8 records
Recent moves12 records
Expansion highlights8 records
VentriPoint Diagnostics competitors and assessment
Company assessmentEmerging players
- Eko Health: Digital stethoscope and cardiac AI company offering FDA-cleared algorithms for heart murmur and AF detection from auscultation. Comparable as an emerging cardiac AI diagnostics player, although it competes at the primary-care/screening layer rather than the specialist echo layer Ventripoint addresses.
- iRhythm Technologies: Digital cardiac ambulatory monitoring company (Zio) using AI on ECG patch data for arrhythmia detection. Comparable as a digitally enabled cardiac diagnostics company selling into cardiology with recurring-revenue economics, although addressing arrhythmia rather than structural/volumetric assessment.
- Cleerly: AI cardiac CT company providing automated plaque quantification and coronary assessment. Adjacent emerging player applying AI to non-invasive cardiac imaging quantification, with overlapping customer (cardiology departments) but different modality (CT vs echo).
Broad incumbents
- Siemens Healthineers (Cardiac Ultrasound): Major cardiac ultrasound vendor (ACUSON SC2000, echo AI features) with broad imaging informatics portfolio. Comparable as a large incumbent that could compete with or absorb Ventripoint-style AI echo quantification functionality inside its installed base.
- Philips (Cardiac Ultrasound / AI): Global incumbent in cardiac ultrasound with integrated AI tools for automated quantification (e.g., Cardiac True Vue, AI-enabled measurements on EPIQ/EchoNavigator). Comparable as a competitor embedding AI cardiac analytics into the dominant hospital imaging platform.
- Caption Health (Caption AI, GE HealthCare): Originally an AI-guided cardiac ultrasound software company (Caption AI) acquired by GE HealthCare in 2023. Now embedded in GE's ultrasound ecosystem as part of its broader portfolio, providing automated cardiac measurement tools at scale across the largest installed base in cardiac ultrasound.
Direct peers
- HeartVista: AI-driven cardiac MRI acquisition and analysis company (FDA-cleared One Click MRI), focused on automating CMR workflows. Comparable in target user (cardiologists) and the thesis of bringing faster, more reproducible cardiac imaging to point of care.
- Us2.ai: Singapore-based AI echocardiography company with FDA-cleared, fully automated echo analysis software that produces measurements comparable to cardiac MRI. Closely comparable in product (AI echo → MRI-quality measurements) and target customers (cardiology departments and clinical trials).
- Ultromics: UK-based AI echocardiography company offering EchoGo, an FDA-cleared platform that automates cardiac ultrasound analysis and decision support. Directly comparable to Ventripoint as a pure-play AI software company targeting AI-driven quantification on top of standard echo machines in cardiology.
- Circle Cardiovascular Imaging: Calgary-based cardiac imaging software company providing CMR (cardiac MRI) and CT post-processing tools used in congenital and structural heart disease. Closely comparable in clinical use case (advanced cardiac quantification, congenital heart disease workflows) though focused on MRI/CT rather than echo.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
VentriPoint Diagnostics social profiles
Digital presenceVentriPoint Diagnostics compliance and trust
Trust signalCompliance3 records
VentriPoint Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
VentriPoint Diagnostics leadership team
Management profileNumber of profiles
Profiles9 records
VentriPoint Diagnostics funding detail
Funding detailFunding overview
Funding rounds13 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VentriPoint Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VentriPoint Diagnostics
What does VentriPoint Diagnostics do?
VentriPoint Diagnostics develops and sells the VMS+ cardiac imaging platform, an AI-powered system that transforms standard 2D echocardiograms into MRI-quality 3D models of the heart. The proprietary Knowledge-Based Reconstruction (KBR) algorithm provides volumetric measurements and ejection fractions for all four heart chambers with cMRI-equivalent accuracy. The platform includes the VMS+ hardware/software system with sensor tracking, a workstation-based 3D Echo and MRI software, and add-on modules such as Global Longitudinal Strain analysis, targeting hospitals, cardiac centers, and remote healthcare providers.
Is VentriPoint Diagnostics a public or private company?
VentriPoint Diagnostics is a public company. It is classified as public and is currently operating.
When was VentriPoint Diagnostics founded?
VentriPoint Diagnostics was founded in 2001. It employs 11 to 50 people.
Where is VentriPoint Diagnostics based?
VentriPoint Diagnostics is headquartered in Toronto, Canada, in the North America region.
How does VentriPoint Diagnostics make money?
Four revenue lines are on record. Device-as-a-Service Subscription is the primary driver. The others are capital Equipment Sales, future Cost-per-Use Model and hardware/Component Sales.
Who are VentriPoint Diagnostics's main competitors?
Emerging players on record are Eko Health, iRhythm Technologies and Cleerly. Broad incumbents are Siemens Healthineers (Cardiac Ultrasound), Philips (Cardiac Ultrasound / AI) and Caption Health (Caption AI, GE HealthCare). Direct peers are HeartVista, Us2.ai, Ultromics and Circle Cardiovascular Imaging.
Does VentriPoint Diagnostics have an API?
No public API is recorded for VentriPoint Diagnostics.
What industry is VentriPoint Diagnostics in?
VentriPoint Diagnostics's product category is Cardiac Diagnostic Imaging Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLACALAE, Imaging Workflow Orchestration & Modality Worklist (MWL)/Scheduling. Its NAICS code is 54151 and its SIC code is 3841.